CXCL10
CXCL10(英語:C-X-C motif chemokine 10)是一小分子的細胞因子屬於CXC趨化因子家族[5],又被稱作「干擾素伽瑪誘導的10千道爾頓蛋白」(10 kDa interferon-gamma-induced protein,IP-10)[6] 。干擾素伽瑪可以在多種細胞(如巨噬細胞[7] ,單核白血球[7] ,內皮細胞[8]和纖維母細胞)中誘導CXCL10的表達。CXCL10的功能包括對T細胞和單核白血球的細胞趨化作用[9][10],促進T細胞黏附於內皮細胞[8],抗腫瘤[11],及血管新生[8]。人類的CXCL10基因與CXCL9,CXCL11的基因相鄰聚集在第四染色體上。CXCL10, CXCL9和CXCL11結合趨化因子受體CXCR3而起其細胞趨化作用[9][10] 。
參見
參考文獻
- ^ 1.0 1.1 1.2 GRCh38: Ensembl release 89: ENSG00000169245 - Ensembl, May 2017
- ^ 2.0 2.1 2.2 GRCm38: Ensembl release 89: ENSMUSG00000034855 - Ensembl, May 2017
- ^ Human PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Mouse PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Liu L, Callahan MK, Huang D, Ransohoff RM. Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol. 2005;68:149-81.
- ^ Kaplan G, Luster AD, Hancock G, Cohn ZA. The expression of a gamma interferon-induced protein (IP-10) in delayed immune responses in human skin. J Exp Med. 1987 Oct 1;166(4):1098-108.
- ^ 7.0 7.1 Narumi S, Hamilton TA. Inducible expression of murine IP-10 mRNA varies with the state of macrophage inflammatory activity. J Immunol. 1991 May 1;146(9):3038-44.
- ^ 8.0 8.1 8.2 Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med. 1995 Jul 1;182(1):155-62.
- ^ 9.0 9.1 Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med. 1996 Sep 1;184(3):963-9.
- ^ 10.0 10.1 Weng Y, Siciliano SJ, Waldburger KE, Sirotina-Meisher A, Staruch MJ, Daugherty BL, Gould SL, Springer MS, DeMartino JA. Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem. 1998 Jul 17;273(29):18288-91.
- ^ Luster AD, Leder P. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med. 1993 Sep 1;178(3):1057-65